Hasan Uludag obtained dual B.Sc. degrees in biomedical engineering and biology from the Brown University in 1989. He then completed his Ph.D. degree in 1993 at the Department of Chemical Engineering and Applied Chemistry at the University of Toronto. He spent four years at Genetics Institute Inc. (now part of Wyeth Pharma) working on commercial development of a new generation of bone-inducing devices based on bone morphogenetic protein-2 (BMP-2) and collagen combination. He joined the University of Alberta (Edmonton, Canada) in 1997, holding joint appointments at the Departments of Chemical and Materials Engineering, Biomedical Engineering, Dentistry, and Faculty of Pharmacy and Pharmaceutical Sciences. Dr. Uludag is currently directing interdisciplinary research programs on designing bone targeting systems for protein therapeutics, and nonviral delivery systems for transgene expression in primary cells. Dr. Uludag is actively involved in various biomaterials societies around the world, and is an elected Fellow of the International Union of Society of Biomaterials Science and Engineering (IUS-BSA).
Biography Updated on 5 June 2008